Pharmaceuticals
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults
* Nuvaxovid™ is New Zealand's first and only protein-based COVID-19 vaccine * Nuvaxovid™ can now be used as a first or second booster dose for adults aged 18 and older vaccinated with any primary series vaccine GAITHERSBURG, Md., Aug. 17, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a bi...
2022-08-17 20:00
2953
JOYSBIO HAS DEVELOPED NEW MONKEYPOX RAPID TESTS
JOYSBIO, one of the world's leading manufacturers of rapid test kits, has developed two new Monkeypox tests that deliver results in 15 minutes TIANJIN, China, Aug. 17, 2022 /PRNewswire/ -- JOYSBIO, one of the world's leading manufacturers of lateral flow rapid test kits, is proud to announce the...
2022-08-17 14:30
2462
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in seco...
2022-08-17 04:05
2538
WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware
MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...
2022-08-17 01:47
4127
STANDIGM WINS GOLD AND BRONZE STEVIE® AWARDS IN 2022 INTERNATIONAL BUSINESS AWARDS®
Winners to Be Celebrated During Event in London on 15 October
SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- Standigm
2022-08-16 20:30
2528
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022
JI'AN, China, Aug. 16, 2022 /PRNewswire/ -- Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022. Mr. Gang Lai, Chairman and ...
2022-08-16 20:00
2663
Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel
PETACH TIKVAH, Israel, Aug. 16, 2022 /PRNewswire/ -- Medison Pharma
2022-08-16 19:30
2325
Profitable growth continues: Exyte with remarkable 6M/2022 results and uplifted year-end outlook
- Order intake rose by almost 50 percent year-on-year, marking a new 6M-high with €4.7 billion - Sales volume increased by almost 50 percent to €3.4 billion - Adjusted EBIT increased by approximately two thirds to €202 million; adjusted EBITDA rose to €222 million, plus over 60 percent - Global...
2022-08-16 16:24
2241
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi ...
2022-08-16 14:48
2707
ICP DAS - BMP will attend MEDICAL MANUFACTURING ASIA 2022 in Singapore
TAIPEI, Aug. 16, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at MEDICAL MANUFACTURINGASIA 2022, the 5th Manufacturing Processes for Medical Technology Exhibition and Conference, which provides excellent busi...
2022-08-16 10:15
2615
Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia
* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitorthat targets the DNA damage response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology...
2022-08-16 08:30
2727
Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study on ASC42 in the U.S. is expected to be completed by the beginning of the fourth quarter 2022 -- This DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more eviden...
2022-08-16 08:10
2287
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-...
2022-08-16 07:15
2697
Seegene reports H1 2022 financial results
* H1 revenue fell 11% YoY to KRW 579.9 billion, operating profit down 37% to KRW 212.7 billion * Decline due to drop in Q2 sales amid reduced PCR testing volume * Sales of non-COVID products and PCR instruments increased in H1; Company launches STARlet-AIOS to strengthen sales foundation *...
2022-08-12 19:00
13459
JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.
SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented at the 2022 IASLC World Conference on Lung Cancer in Vienna, Austria on 8th August, at the official session "Overcomin...
2022-08-12 10:13
1638
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
* Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be availablefor patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer * Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrantshowing st...
2022-08-11 20:08
2985
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan
Taiwan FDA accepts New Drug Application for Xerava for treatment of cIAI
Everest enters into strategic partnership with TTY Biopharm for the
commercialization of Xerava inTaiwan
SHANGHAI, Aug. 11, 2022 /PRNewswire/ -- Everest Medicines
2022-08-11 08:00
2540
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers
SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient inAustralia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients. Globally, Arbele is the first company exploring...
2022-08-10 20:00
1525
Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board
An expert in genitourinary oncology, Dr. Konety brings deep academic insight, broad clinical expertise and a global network to help Asieris advance its innovative pipeline to serve patients worldwide. SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (stock code: 688176.SH), a glob...
2022-08-10 16:09
1489
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC,Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibod...
2022-08-10 15:29
1660
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 317 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 287 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
10615
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
7522
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
6790
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
6390
